JP2010512313A5 - - Google Patents
Download PDFInfo
- Publication number
- JP2010512313A5 JP2010512313A5 JP2009540285A JP2009540285A JP2010512313A5 JP 2010512313 A5 JP2010512313 A5 JP 2010512313A5 JP 2009540285 A JP2009540285 A JP 2009540285A JP 2009540285 A JP2009540285 A JP 2009540285A JP 2010512313 A5 JP2010512313 A5 JP 2010512313A5
- Authority
- JP
- Japan
- Prior art keywords
- therapeutic composition
- severe
- monoclonal antibody
- human subject
- sle
- Prior art date
- Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
- Pending
Links
- 230000001225 therapeutic effect Effects 0.000 claims 26
- 201000000596 systemic lupus erythematosus Diseases 0.000 claims 11
- 230000001064 anti-interferon Effects 0.000 claims 4
- 238000002203 pretreatment Methods 0.000 claims 4
- 102000006992 Interferon-alpha Human genes 0.000 claims 3
- 108010047761 Interferon-alpha Proteins 0.000 claims 3
- 239000003246 corticosteroid Substances 0.000 claims 3
- 239000003814 drug Substances 0.000 claims 2
- JYGXADMDTFJGBT-VWUMJDOOSA-N hydrocortisone Chemical compound O=C1CC[C@]2(C)[C@H]3[C@@H](O)C[C@](C)([C@@](CC4)(O)C(=O)CO)[C@@H]4[C@@H]3CCC2=C1 JYGXADMDTFJGBT-VWUMJDOOSA-N 0.000 claims 2
- 229960004618 prednisone Drugs 0.000 claims 2
- XOFYZVNMUHMLCC-ZPOLXVRWSA-N prednisone Chemical compound O=C1C=C[C@]2(C)[C@H]3C(=O)C[C@](C)([C@@](CC4)(O)C(=O)CO)[C@@H]4[C@@H]3CCC2=C1 XOFYZVNMUHMLCC-ZPOLXVRWSA-N 0.000 claims 2
- 229940124597 therapeutic agent Drugs 0.000 claims 2
- VHRSUDSXCMQTMA-PJHHCJLFSA-N 6alpha-methylprednisolone Chemical compound C([C@@]12C)=CC(=O)C=C1[C@@H](C)C[C@@H]1[C@@H]2[C@@H](O)C[C@]2(C)[C@@](O)(C(=O)CO)CC[C@H]21 VHRSUDSXCMQTMA-PJHHCJLFSA-N 0.000 claims 1
- -1 NSAIDS Substances 0.000 claims 1
- 239000003146 anticoagulant agent Substances 0.000 claims 1
- 229940127219 anticoagulant drug Drugs 0.000 claims 1
- 239000003430 antimalarial agent Substances 0.000 claims 1
- 229940033495 antimalarials Drugs 0.000 claims 1
- 229960002537 betamethasone Drugs 0.000 claims 1
- UREBDLICKHMUKA-DVTGEIKXSA-N betamethasone Chemical compound C1CC2=CC(=O)C=C[C@]2(C)[C@]2(F)[C@@H]1[C@@H]1C[C@H](C)[C@@](C(=O)CO)(O)[C@@]1(C)C[C@@H]2O UREBDLICKHMUKA-DVTGEIKXSA-N 0.000 claims 1
- 229960001334 corticosteroids Drugs 0.000 claims 1
- 229960003957 dexamethasone Drugs 0.000 claims 1
- UREBDLICKHMUKA-CXSFZGCWSA-N dexamethasone Chemical compound C1CC2=CC(=O)C=C[C@]2(C)[C@]2(F)[C@@H]1[C@@H]1C[C@@H](C)[C@@](C(=O)CO)(O)[C@@]1(C)C[C@@H]2O UREBDLICKHMUKA-CXSFZGCWSA-N 0.000 claims 1
- 229960000890 hydrocortisone Drugs 0.000 claims 1
- 239000002955 immunomodulating agent Substances 0.000 claims 1
- 229940121354 immunomodulator Drugs 0.000 claims 1
- 229960004584 methylprednisolone Drugs 0.000 claims 1
- 229940021182 non-steroidal anti-inflammatory drug Drugs 0.000 claims 1
- 229960005205 prednisolone Drugs 0.000 claims 1
- OIGNJSKKLXVSLS-VWUMJDOOSA-N prednisolone Chemical compound O=C1C=C[C@]2(C)[C@H]3[C@@H](O)C[C@](C)([C@@](CC4)(O)C(=O)CO)[C@@H]4[C@@H]3CCC2=C1 OIGNJSKKLXVSLS-VWUMJDOOSA-N 0.000 claims 1
- 229960005294 triamcinolone Drugs 0.000 claims 1
- GFNANZIMVAIWHM-OBYCQNJPSA-N triamcinolone Chemical compound O=C1C=C[C@]2(C)[C@@]3(F)[C@@H](O)C[C@](C)([C@@]([C@H](O)C4)(O)C(=O)CO)[C@@H]4[C@@H]3CCC2=C1 GFNANZIMVAIWHM-OBYCQNJPSA-N 0.000 claims 1
Applications Claiming Priority (13)
| Application Number | Priority Date | Filing Date | Title |
|---|---|---|---|
| US87300806P | 2006-12-06 | 2006-12-06 | |
| US90776207P | 2007-04-16 | 2007-04-16 | |
| US90776707P | 2007-04-16 | 2007-04-16 | |
| US92421907P | 2007-05-03 | 2007-05-03 | |
| US92422007P | 2007-05-03 | 2007-05-03 | |
| US92458407P | 2007-05-21 | 2007-05-21 | |
| US96018707P | 2007-09-19 | 2007-09-19 | |
| US99617607P | 2007-11-05 | 2007-11-05 | |
| US99617407P | 2007-11-05 | 2007-11-05 | |
| US99621907P | 2007-11-06 | 2007-11-06 | |
| US99682007P | 2007-12-06 | 2007-12-06 | |
| PCT/US2007/024941 WO2008070135A2 (en) | 2006-12-06 | 2007-12-06 | Methods of treating systemic lupus erythematosus |
| PCT/US2007/024947 WO2008070137A2 (en) | 2006-12-06 | 2007-12-06 | Interferon alpha-induced pharmacodynamic markers |
Related Child Applications (1)
| Application Number | Title | Priority Date | Filing Date |
|---|---|---|---|
| JP2013193959A Division JP2014040430A (ja) | 2006-12-06 | 2013-09-19 | 全身性エリテマトーデスの治療方法 |
Publications (2)
| Publication Number | Publication Date |
|---|---|
| JP2010512313A JP2010512313A (ja) | 2010-04-22 |
| JP2010512313A5 true JP2010512313A5 (enExample) | 2011-02-10 |
Family
ID=39492862
Family Applications (4)
| Application Number | Title | Priority Date | Filing Date |
|---|---|---|---|
| JP2009540288A Pending JP2010512315A (ja) | 2006-12-06 | 2007-12-06 | インターフェロンα誘導性薬力学的マーカー |
| JP2009540285A Pending JP2010512313A (ja) | 2006-12-06 | 2007-12-06 | 全身性エリテマトーデスの治療方法 |
| JP2013183939A Pending JP2014014370A (ja) | 2006-12-06 | 2013-09-05 | インターフェロンα誘導性薬力学的マーカー |
| JP2013193959A Pending JP2014040430A (ja) | 2006-12-06 | 2013-09-19 | 全身性エリテマトーデスの治療方法 |
Family Applications Before (1)
| Application Number | Title | Priority Date | Filing Date |
|---|---|---|---|
| JP2009540288A Pending JP2010512315A (ja) | 2006-12-06 | 2007-12-06 | インターフェロンα誘導性薬力学的マーカー |
Family Applications After (2)
| Application Number | Title | Priority Date | Filing Date |
|---|---|---|---|
| JP2013183939A Pending JP2014014370A (ja) | 2006-12-06 | 2013-09-05 | インターフェロンα誘導性薬力学的マーカー |
| JP2013193959A Pending JP2014040430A (ja) | 2006-12-06 | 2013-09-19 | 全身性エリテマトーデスの治療方法 |
Country Status (10)
| Country | Link |
|---|---|
| US (5) | US20100143373A1 (enExample) |
| EP (3) | EP2712930A3 (enExample) |
| JP (4) | JP2010512315A (enExample) |
| KR (2) | KR20090088932A (enExample) |
| AU (2) | AU2007327995B2 (enExample) |
| BR (2) | BRPI0720035A2 (enExample) |
| CA (2) | CA2670897A1 (enExample) |
| MX (1) | MX2009005787A (enExample) |
| RU (2) | RU2527068C2 (enExample) |
| WO (2) | WO2008070135A2 (enExample) |
Families Citing this family (47)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| JP2010512315A (ja) * | 2006-12-06 | 2010-04-22 | メディミューン，エルエルシー | インターフェロンα誘導性薬力学的マーカー |
| CA2685147A1 (en) * | 2007-05-03 | 2008-11-13 | Medimmune, Llc | Auto-antibody markers of autoimmune disease |
| JP5726524B2 (ja) * | 2007-07-12 | 2015-06-03 | ザ ブリガム アンド ウィメンズ ホスピタル インコーポレイテッドＴｈｅ Ｂｒｉｇｈａｍ ａｎｄ Ｗｏｍｅｎ’ｓ Ｈｏｓｐｉｔａｌ， Ｉｎｃ． | 炎症性筋障害を診断および評価するための組成物および方法 |
| BRPI0819195A2 (pt) | 2007-11-05 | 2017-05-23 | Medimmune Llc | métodos para tratar escleroderma em um paciente em necessidade de tal tratamento e para aliviar um ou mais dos sintomas associados com escleroderma em um paciente em necessidade de tal tratamento. |
| MX2010008698A (es) * | 2008-02-08 | 2010-12-20 | Medimmune Llc | Marcadores de enfermedad y usos de los mismos. |
| AU2010289383B2 (en) * | 2009-09-03 | 2015-04-16 | Medimmune, Llc | Type 1 interferon diagnostic |
| US9128101B2 (en) | 2010-03-01 | 2015-09-08 | Caris Life Sciences Switzerland Holdings Gmbh | Biomarkers for theranostics |
| WO2011127219A1 (en) | 2010-04-06 | 2011-10-13 | Caris Life Sciences Luxembourg Holdings | Circulating biomarkers for disease |
| US9709565B2 (en) | 2010-04-21 | 2017-07-18 | Memed Diagnostics Ltd. | Signatures and determinants for distinguishing between a bacterial and viral infection and methods of use thereof |
| JP2014501263A (ja) * | 2010-12-22 | 2014-01-20 | ザ・フェインスタイン・インスティチュート・フォー・メディカル・リサーチ | Ｈｉｖプロテアーゼ阻害剤を用いて全身性エリテマトーデスを治療する方法 |
| AU2013204880B2 (en) * | 2011-04-26 | 2016-11-24 | Genentech, Inc. | Compositions and method for treating autoimmune diseases |
| JP6211513B2 (ja) * | 2011-04-26 | 2017-10-11 | ジェネンテック， インコーポレイテッド | 自己免疫疾患の治療のための組成物及び方法 |
| GB201115665D0 (en) | 2011-09-09 | 2011-10-26 | Univ Leuven Kath | Autoimmune and inflammatory disorder therapy |
| MX339762B (es) | 2011-09-28 | 2016-05-27 | Univ Autonoma Del Estado De Morelos | Metalopeptidos inmunomoduladores (immp) y composiciones que los contienen. |
| WO2013101771A2 (en) | 2011-12-30 | 2013-07-04 | Genentech, Inc. | Compositions and method for treating autoimmune diseases |
| CA2863819C (en) | 2012-02-09 | 2021-11-23 | Memed Diagnostics Ltd. | Signatures and determinants for diagnosing infections and methods of use thereof |
| EP2850437A4 (en) | 2012-05-17 | 2016-01-13 | Univ Johns Hopkins | METHOD FOR IDENTIFYING PATTERNS OF IFN-INDUCED EXPRESSION AND USE FOR DIAGNOSIS, MONITORING AND THERAPY PURPOSES |
| KR102185237B1 (ko) * | 2012-06-13 | 2020-12-02 | 아스트라제네카 아베 | 항-i형 인터페론 수용체(ifnar) 항체에 대한 고정 투여 계획 |
| US20140156297A1 (en) * | 2012-08-03 | 2014-06-05 | Axelacare Holdings, Inc. | Computer program, method, and system for pharmacist-assisted treatment of patients |
| US20140039907A1 (en) * | 2012-08-03 | 2014-02-06 | AxelaCare Health Solutions, Inc. | Computer program, method, and system for collecting patient data with a portable electronic device |
| US20140275257A1 (en) * | 2013-03-14 | 2014-09-18 | Foundation for the State University of New York | N-acetyl cysteine compositions in the treatment of systemic lupus erythematosus |
| US10303846B2 (en) | 2014-08-14 | 2019-05-28 | Memed Diagnostics Ltd. | Computational analysis of biological data using manifold and a hyperplane |
| CN105420347A (zh) * | 2014-08-21 | 2016-03-23 | 南京大学医学院附属鼓楼医院 | 一种用于系统性红斑狼疮的基因诊断试剂盒 |
| US20170234873A1 (en) | 2014-10-14 | 2017-08-17 | Memed Diagnostics Ltd. | Signatures and determinants for diagnosing infections in non-human subjects and methods of use thereof |
| US20170269081A1 (en) | 2014-12-11 | 2017-09-21 | Memed Diagnostics Ltd. | Marker combinations for diagnosing infections and methods of use thereof |
| CN108699609A (zh) | 2016-03-03 | 2018-10-23 | 米密德诊断学有限公司 | 分析rna用于诊断感染类型 |
| WO2017149548A1 (en) | 2016-03-03 | 2017-09-08 | Memed Diagnostics Ltd. | Rna determinants for distinguishing between bacterial and viral infections |
| US11340223B2 (en) | 2016-07-10 | 2022-05-24 | Memed Diagnostics Ltd. | Early diagnosis of infections |
| CA3027341A1 (en) | 2016-07-10 | 2018-01-18 | Memed Diagnostics Ltd. | Protein signatures for distinguishing between bacterial and viral infections |
| US11353456B2 (en) | 2016-09-29 | 2022-06-07 | Memed Diagnostics Ltd. | Methods of risk assessment and disease classification for appendicitis |
| EP3519833B1 (en) | 2016-09-29 | 2024-08-14 | MeMed Diagnostics Ltd. | Methods of prognosis and treatment |
| WO2018112464A1 (en) * | 2016-12-16 | 2018-06-21 | The Penn State Research Foundation | Methods for improved reproductive management of ruminant ungulates |
| WO2018136625A2 (en) * | 2017-01-20 | 2018-07-26 | Children's Medical Center Corporation | Compositions and methods for treating diseases characterized by reactive microglia mediated synapse loss |
| US10209260B2 (en) | 2017-07-05 | 2019-02-19 | Memed Diagnostics Ltd. | Signatures and determinants for diagnosing infections and methods of use thereof |
| WO2019020593A1 (en) * | 2017-07-25 | 2019-01-31 | INSERM (Institut National de la Santé et de la Recherche Médicale) | METHODS AND PHARMACEUTICAL COMPOSITIONS FOR MODULATION OF MONOCYTOPOISIS |
| US12331320B2 (en) | 2018-10-10 | 2025-06-17 | The Research Foundation For The State University Of New York | Genome edited cancer cell vaccines |
| KR20210084528A (ko) * | 2018-10-26 | 2021-07-07 | 얀센 바이오테크 인코포레이티드 | I형 인터페론 시그너처 및 사용 방법 |
| JP7558167B2 (ja) | 2018-12-03 | 2024-09-30 | ボード オブ リージェンツ，ザ ユニバーシティ オブ テキサス システム | オリゴベンズアミド類似体およびがん処置におけるそれらの使用 |
| SG11202108679PA (en) | 2019-02-15 | 2021-09-29 | Astrazeneca Ab | Type i interferon-mediated disorders |
| US12011284B2 (en) * | 2020-05-19 | 2024-06-18 | Peachy Corp. | Systems and methods for preventing and treating wrinkles |
| KR102429261B1 (ko) | 2020-08-25 | 2022-08-03 | 충북대학교 산학협력단 | 한국인의 tnf 저해제 약물 반응성 예측을 위한 바이오마커 |
| JP2023544351A (ja) * | 2020-10-02 | 2023-10-23 | セルジーン コーポレーション | 全身性エリテマトーデスを治療する方法及び治療に対する臨床的感受性の予測因子としてのバイオマーカの使用 |
| HRP20231255T1 (hr) | 2021-04-23 | 2024-02-02 | Astrazeneca Ab | Režim doziranja anti-ifnar1 za potkožnu injekciju |
| EP4355759A4 (en) | 2021-06-18 | 2026-05-13 | Ionis Pharmaceuticals Inc | COMPOUNDS AND METHODS FOR REDUCING THE EXPRESSION OF IFNAR1 |
| FR3138815A1 (fr) * | 2022-08-12 | 2024-02-16 | bioMérieux | Détermination de la nature virale ou bactérienne d’une infection |
| CN117305441B (zh) * | 2023-10-13 | 2025-04-08 | 福建农林大学 | 一种2型糖尿病的生物标志物和治疗靶点及浒苔寡糖的应用方法 |
| WO2025213238A1 (en) * | 2024-04-12 | 2025-10-16 | HaemaLogiX Ltd | Anti-kma antibody formulations |
Family Cites Families (35)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| EP0139676B1 (en) | 1983-02-04 | 1992-11-25 | Cytoclonal Pharmaceutics Inc. | Production and characterization of hybridoma antibodies directed specifically against common determinant(s) present among closely related, but distinct proteins |
| GB8303165D0 (en) | 1983-02-04 | 1983-03-09 | Secher D S | Monoclonal antibody |
| DE3306060A1 (de) | 1983-02-22 | 1984-08-23 | Boehringer Ingelheim International GmbH, 6507 Ingelheim | Neue immunglobulin-produzierende hybridzellinien, deren verwendung und verfahren zu deren herstellung |
| DE3685996T2 (de) | 1985-06-11 | 1993-01-14 | Ciba Geigy Ag | Hybrid-interferone. |
| US5744101A (en) | 1989-06-07 | 1998-04-28 | Affymax Technologies N.V. | Photolabile nucleoside protecting groups |
| US5143854A (en) | 1989-06-07 | 1992-09-01 | Affymax Technologies N.V. | Large scale photolithographic solid phase synthesis of polypeptides and receptor binding screening thereof |
| FR2692168B1 (fr) | 1992-06-16 | 1995-03-24 | Centre Nat Rech Scient | Préparation et utilisation de nouveaux systèmes colloïdaux dispersibles à base de cyclodextrine, sous forme de nanosphères. |
| US5888511A (en) * | 1993-02-26 | 1999-03-30 | Advanced Biotherapy Concepts, Inc. | Treatment of autoimmune diseases, including AIDS |
| CA2186118C (en) | 1994-03-23 | 2010-10-19 | Richard W. Hanson | Compacted nucleic acids and their delivery to cells |
| US6077835A (en) | 1994-03-23 | 2000-06-20 | Case Western Reserve University | Delivery of compacted nucleic acid to cells |
| US5972901A (en) | 1994-03-23 | 1999-10-26 | Case Western Reserve University | Serpin enzyme complex receptor--mediated gene transfer |
| US6905587B2 (en) * | 1996-03-22 | 2005-06-14 | Ronald Redline | Method for enhancing the solderability of a surface |
| AU749032B2 (en) | 1997-06-13 | 2002-06-20 | Johns Hopkins University, The | Therapeutic nanospheres |
| AU757961B2 (en) * | 1998-09-30 | 2003-03-13 | Sankyo Company Limited | Anti-Fas antibodies |
| US20050008683A1 (en) * | 2000-06-29 | 2005-01-13 | Becton Dickinson And Company | Method for delivering interferons to the intradermal compartment |
| US7087726B2 (en) * | 2001-02-22 | 2006-08-08 | Genentech, Inc. | Anti-interferon-α antibodies |
| US6905827B2 (en) * | 2001-06-08 | 2005-06-14 | Expression Diagnostics, Inc. | Methods and compositions for diagnosing or monitoring auto immune and chronic inflammatory diseases |
| EP1463761A1 (en) * | 2001-11-30 | 2004-10-06 | Innogenetics N.V. | Therapeutic use of antibodies and fragments thereof binding primate ifn-gamma |
| EP2329827A3 (en) * | 2002-11-21 | 2011-07-13 | Bayhill Therapeutics, Inc. | Methods and immune modulatory nucleic acid compositions for preventing and treating disease |
| US7550263B2 (en) * | 2003-09-05 | 2009-06-23 | Gtc Biotherapeutics, Inc. | Method for the production of fusion proteins in transgenic mammal milk |
| ES2399050T3 (es) * | 2003-12-10 | 2013-03-25 | Medarex, Inc. | Anticuerpos contra interferón alfa y sus usos |
| KR20150041193A (ko) * | 2004-06-21 | 2015-04-15 | 메다렉스, 엘.엘.시. | 인터페론 알파 수용체 1 항체 및 그의 용도 |
| US20070166281A1 (en) * | 2004-08-21 | 2007-07-19 | Kosak Kenneth M | Chloroquine coupled antibodies and other proteins with methods for their synthesis |
| WO2006023966A2 (en) * | 2004-08-24 | 2006-03-02 | The Trustees Of The University Of Pennsylvania Center For Technology Transfer | Assessment of cardiovascular risk |
| US7571055B2 (en) * | 2004-10-13 | 2009-08-04 | Regents Of The University Of Minnesota | Systemic lupus erythematosus |
| JP5837730B2 (ja) * | 2005-02-10 | 2015-12-24 | ベイラー リサーチ インスティテュートＢａｙｌｏｒ Ｒｅｓｅａｒｃｈ Ｉｎｓｔｉｔｕｔｅ | 抗インターフェロンアルファモノクローナル抗体及び使用方法 |
| US20070117105A1 (en) * | 2005-05-12 | 2007-05-24 | Crow Mary K | Interferon assay |
| US20070065844A1 (en) * | 2005-06-08 | 2007-03-22 | Massachusetts Institute Of Technology | Solution-based methods for RNA expression profiling |
| AU2006278561C1 (en) * | 2005-08-05 | 2013-05-02 | Genentech, Inc. | Methods and compositions for detecting autoimmune disorders |
| US7608395B2 (en) * | 2005-09-15 | 2009-10-27 | Baylor Research Institute | Systemic lupus erythematosus diagnostic assay |
| CA2626082C (en) * | 2005-10-13 | 2017-04-11 | Human Genome Sciences, Inc. | Methods and compositions for use in treatment of patients with autoantibody positive disease |
| JP5230022B2 (ja) * | 2006-08-09 | 2013-07-10 | ベイラー リサーチ インスティテュート | 抗インターフェロンアルファモノクローナル抗体及び使用方法 |
| JP2010512315A (ja) * | 2006-12-06 | 2010-04-22 | メディミューン，エルエルシー | インターフェロンα誘導性薬力学的マーカー |
| US20100209434A1 (en) * | 2007-03-30 | 2010-08-19 | Medimmune, Llc | Antibody formulation |
| AU2010289383B2 (en) * | 2009-09-03 | 2015-04-16 | Medimmune, Llc | Type 1 interferon diagnostic |
-
2007
- 2007-12-06 JP JP2009540288A patent/JP2010512315A/ja active Pending
- 2007-12-06 AU AU2007327995A patent/AU2007327995B2/en not_active Ceased
- 2007-12-06 BR BRPI0720035-8A patent/BRPI0720035A2/pt active Search and Examination
- 2007-12-06 EP EP13179923.1A patent/EP2712930A3/en not_active Withdrawn
- 2007-12-06 MX MX2009005787A patent/MX2009005787A/es active IP Right Grant
- 2007-12-06 WO PCT/US2007/024941 patent/WO2008070135A2/en not_active Ceased
- 2007-12-06 US US12/517,334 patent/US20100143373A1/en not_active Abandoned
- 2007-12-06 CA CA002670897A patent/CA2670897A1/en not_active Abandoned
- 2007-12-06 CA CA002670594A patent/CA2670594A1/en not_active Abandoned
- 2007-12-06 US US12/517,333 patent/US20100143372A1/en not_active Abandoned
- 2007-12-06 AU AU2007327993A patent/AU2007327993B2/en not_active Ceased
- 2007-12-06 EP EP07867637A patent/EP2077858A4/en not_active Ceased
- 2007-12-06 BR BRPI0719912-0A2A patent/BRPI0719912A2/pt not_active IP Right Cessation
- 2007-12-06 WO PCT/US2007/024947 patent/WO2008070137A2/en not_active Ceased
- 2007-12-06 KR KR1020097013891A patent/KR20090088932A/ko not_active Ceased
- 2007-12-06 JP JP2009540285A patent/JP2010512313A/ja active Pending
- 2007-12-06 EP EP07867634A patent/EP2073844A4/en not_active Ceased
- 2007-12-06 RU RU2009125616/10A patent/RU2527068C2/ru not_active IP Right Cessation
- 2007-12-06 KR KR1020097013872A patent/KR101532797B1/ko not_active Expired - Fee Related
-
2013
- 2013-09-05 JP JP2013183939A patent/JP2014014370A/ja active Pending
- 2013-09-19 JP JP2013193959A patent/JP2014040430A/ja active Pending
-
2014
- 2014-07-03 RU RU2014127178A patent/RU2014127178A/ru not_active Application Discontinuation
- 2014-07-14 US US14/330,609 patent/US20150044222A1/en not_active Abandoned
-
2015
- 2015-01-27 US US14/606,832 patent/US20150147336A1/en not_active Abandoned
-
2016
- 2016-10-11 US US15/290,925 patent/US20170121771A1/en not_active Abandoned
Similar Documents
| Publication | Publication Date | Title |
|---|---|---|
| Palandri et al. | Have splenectomy rate and main outcomes of ITP changed after the introduction of new treatments? A monocentric study in the outpatient setting during 35 years | |
| JP2012053071A5 (enExample) | ||
| JP2016538270A5 (enExample) | ||
| HRP20201307T1 (hr) | Upotreba reslizumaba za liječenje umjerene do ozbiljne eozinofilne astme | |
| HRP20230864T1 (hr) | Pd-1 blokada nivolumabom kod refraktornog hodgkinovog limfoma | |
| Pungpapong et al. | Multicenter Experience using Sofosbuvir and Simeprevir with/without Ribavirin to Treat HCV Genotype 1 after Liver Transplantation: 9 | |
| JP2018522891A5 (enExample) | ||
| JP2007506681A5 (enExample) | ||
| WO2015104596A1 (en) | Vasoactive intestinal peptide | |
| Saiki et al. | Successful extension of tocilizumab infusion intervals from 4 weeks to 6 or 5 weeks in 90% of RA patients with good response to 4-week intervals | |
| RU2009125615A (ru) | Способы лечения системной красной волчанки | |
| IL312514A (en) | Corticosteroid reduction in treatment with anti-cd38 antibodies | |
| Baili et al. | AB0709 Association of tinu, nodal tuberculosis and renal amylosis | |
| Neunert | Updates in Immune Thrombocytopenia: Terminology, Immunomodulation and Platelet Stimulation, and Clinical Guidelines and Management | |
| Jayaweera et al. | Effectiveness and safety of cyclosporin A therapy in steroid dependent nephrotic syndrome in childhood | |
| Fabri et al. | Extrahepatic manifestations of chronic hepatitis C and their influence on response to treatment with pegylated interferon alfa-2a and ribavirin | |
| Rossi et al. | AB0707 Tocilizumab as a therapeutic option for rhupus patients refractory to conventional therapy | |
| Panat et al. | Pulse therapy: A boon or bane | |
| Thelengana et al. | A case of relapsing-remitting CIDP with sixth nerve palsy | |
| Cavalli et al. | AB0708 Efficacy of oral tacrolimus in two patients with scleritis and relapsing polychondritis | |
| Hakrush et al. | A46 EOSINOPHILS AND COPD: Peripheral Blood Eeosinophilia As A Predictor Of Severe Chronic Obstructive Pulmonary Disease (COPD) Exacerbations: A Retrospective Study | |
| Aggarwal | A Narrative Review of Acthar Gel for the Treatment of Myositis | |
| Bateman et al. | C22 I FEEL FINE NOW: NEW TREATMENTS FOR COPD: Withdrawal Of Inhaled Corticosteroids And Exacerbations Of COPD: The Wisdom Phenotyping Substudy | |
| Borkar et al. | Interferons and Intravenous Immunoglobulin | |
| Gavrila et al. | Compound A (CpdA) suppressed production of corticosteroid-resistant chemokines via GR-independent mechanisms in airway smooth muscle (ASM) cells |